Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan 75 mg versus 10 mg in pulmonary arterial hypertension
2024-515669-32-00Phase 3Authorised
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial of macitentan and macitentan + tadalafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Time to first CEC-adjudicated morbidity/mortality event on-treatment. Planned start Jul 2024; status: authorised.
02
Drugs
macitentanmacitentan + tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-515669-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515669-32-00.